The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib
Open accessAbstract
The oral multitargeted kinase inhibitors (MTKI) sunitinib (SU11248, Sutent; Pfizer, New York) and sorafenib (BAY 43-9006, Nexavar; Bayer Pharmaceuticals, West Haven, CT, and Onyx Pharmaceuticals, Emeryville, CA) are increasingly used to treat malignant solid tumors. These small-molecule agents inhibit signaling through receptor tyrosine kinases such as vascular endothelial growth factor (VEGF) receptor, platelet-derived growth factor receptor, and c-KIT, among others ( 1 ). In the kidney, glomerular podocytes express VEGF and glomerular endothelial cells express VEGF receptors. Podocyte-specific deletion of a single VEGF allele causes proteinuria and capillary endotheliosis in rodents, and disrupted glomerular VEGF signaling is strongly implicated in the pathogenesis of human preeclampsia ( 2– 4 ). In the institutional review board–approved case series described here, seven patients developed a preeclampsia-like syndrome characterized by hypertension and proteinuria after starting therapy with MTKI. Patients were identified clinically after developing edema, hypertension, proteinuria, and/or hypoalbuminemia ( Table 1 ). New or exacerbated hypertension required on average two additional antihypertensive medications and occurred on average 27 weeks after the start of therapy (range, 2–116 weeks). All seven patients developed proteinuria (average 3.8 g/g, range 1.1–10.4 g/g), with peak urine protein excretion occurring at a median of 24 weeks. There was no serologic evidence of glomerulonephritis or microangiopathic hemolytic anemia in four patients tested. In most patients, the MTKI dose was either reduced or discontinued. Subsequently, in patients with follow-up information, there was dramatic improvement (patients 1, 2, 3), with one patient whose proteinuria was not further quantified except by urinalysis (patient 7). Since 2003, at least 298 patients have been treated with sunitinib or sorafenib at our institutions; thus, the cumulative crude incidence of renal adverse events is 2.3%. However, the true prevalence of MTKI-associated renal toxicity is likely higher because patients were not routinely screened in a systematic, prospective, and long-term manner for the development of new proteinuria. Characterization of hypertension and proteinuria on sunitinib and sorafenib * HTN = hypertension; MTKI = multitargeted tyrosine kinase inhibitor; BP = blood pressure; g/g = gram of urine protein per gram of urine creatinine; F = female; M = male; GIST = gastrointestinal stromal tumor; EHE = epithelioid hemangio-endothelioma; f/b = followed by; NA = not applicable; TCS = teratocarinosarcoma; UA = urinalysis. Toxicity defined as time of onset of proteinuria or hypertension, whichever came first. BP = average of three blood pressure readings (except patients 5, 6, and 7, who had single readings). Weeks elapsed when peak blood pressure was recorded. Characterization of hypertension and proteinuria on sunitinib and sorafenib * HTN = hypertension; MTKI = multitargeted tyrosine kinase inhibitor; BP = blood pressure; g/g = gram of urine protein per gram of urine creatinine; F = female; M = male; GIST = gastrointestinal stromal tumor; EHE = epithelioid hemangio-endothelioma; f/b = followed by; NA = not applicable; TCS = teratocarinosarcoma; UA = urinalysis. Toxicity defined as time of onset of proteinuria or hypertension, whichever came first. BP = average of three blood pressure readings (except patients 5, 6, and 7, who had single readings). Weeks elapsed when peak blood pressure was recorded. VEGF antagonism in rodents reproduces the clinical and pathologic characteristics of preeclampsia, suggesting that inhibition of glomerular VEGF receptor signaling by MTKI is a plausible mechanism to account for the renal toxic effects we observe. Additional evidence for this is that bevacizumab (Avastin; Genentech, South San Francisco, CA), a VEGF-depleting humanized monoclonal antibody, is associated with a dose-dependent risk of proteinuria and hypertension ( 5 ). The gradual rise in blood pressure observed in this series may reflect the delayed development of glomerular endotheliosis. Hypertension and/or proteinuria are probably shared toxic effects among all antiangiogenic therapies targeting the VEGF pathway. In a phase 1 trial of the small-molecule VEGF receptor antagonist KRN951, 14 of 15 patients developed hypertension and three patients developed dose-limiting proteinuria ( 6 ). MTKI-associated renal toxic effects appear to be reversible if detected early enough. All patients starting antiangiogenic therapy should undergo a baseline urinalysis with regular surveillance throughout the course of therapy, in addition to close monitoring of blood pressure and renal function. In patients receiving antiangiogenic therapy, the development of hypertension may be a biomarker of effective VEGF signaling inhibition and superior antitumor activity ( 7 ). Whether the development of proteinuria might also serve as a surrogate marker of
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Self-citation
Cited by
Pre-eclampsia: pathogenesis, novel diagnostics and therapies
Phipps, E. A., Thadhani, R., Benzing, T., & Karumanchi, S. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0119-6 · Cited by 1,191
Young, B. C., Levine, R. J., & Karumanchi, S. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102149 · Cited by 719
Angiogenic Factors and Preeclampsia
Maynard, S. E., & Karumanchi, S. A. (2011) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2010.10.004 · Cited by 466
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
Izzedine, H., Massard, C., Spano, J. P., Goldwasser, F., Khayat, D., & Soria, J. C. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.11.001 · Cited by 332
Molecular mechanisms of preeclampsia
Mutter, W. P., & Karumanchi, S. A. (2008) · Microvascular Research · doi:10.1016/j.mvr.2007.04.009 · Cited by 314
Metadata
- Authors
- Patel, T. V., Morgan, J. A., Demetri, G. D., George, S., Maki, R. G., Quigley, M., & Humphreys, B. D.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-12
- Volume
- 100
- Issue
- 4
- Pages
- 282-284
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2142650045
- Cited by
- 192
- References
- 1
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib. https://app.cochat.ai/papers/10.1093/jnci/djm311
- The paper
- Patel, T. V., Morgan, J. A., Demetri, G. D., George, S., Maki, R. G., Quigley, M., & Humphreys, B. D. (2008). A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djm311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.